1. Home
  2. XOMAP vs MANH Comparison

XOMAP vs MANH Comparison

Compare XOMAP & MANH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • XOMAP
  • MANH
  • Stock Information
  • Founded
  • XOMAP N/A
  • MANH 1990
  • Country
  • XOMAP United States
  • MANH United States
  • Employees
  • XOMAP 13
  • MANH N/A
  • Industry
  • XOMAP Biotechnology: Pharmaceutical Preparations
  • MANH Computer Software: Prepackaged Software
  • Sector
  • XOMAP Health Care
  • MANH Technology
  • Exchange
  • XOMAP Nasdaq
  • MANH Nasdaq
  • Market Cap
  • XOMAP N/A
  • MANH N/A
  • IPO Year
  • XOMAP N/A
  • MANH 1998
  • Fundamental
  • Price
  • XOMAP $25.42
  • MANH $218.59
  • Analyst Decision
  • XOMAP
  • MANH Strong Buy
  • Analyst Count
  • XOMAP 0
  • MANH 7
  • Target Price
  • XOMAP N/A
  • MANH $248.86
  • AVG Volume (30 Days)
  • XOMAP N/A
  • MANH 514.0K
  • Earning Date
  • XOMAP N/A
  • MANH 07-23-2024
  • Dividend Yield
  • XOMAP N/A
  • MANH N/A
  • EPS Growth
  • XOMAP N/A
  • MANH 39.91
  • EPS
  • XOMAP N/A
  • MANH 3.05
  • Revenue
  • XOMAP N/A
  • MANH $962,264,000.00
  • Revenue This Year
  • XOMAP N/A
  • MANH $13.27
  • Revenue Next Year
  • XOMAP N/A
  • MANH $11.60
  • P/E Ratio
  • XOMAP N/A
  • MANH $71.67
  • Revenue Growth
  • XOMAP N/A
  • MANH 18.92
  • 52 Week Low
  • XOMAP N/A
  • MANH $182.97
  • 52 Week High
  • XOMAP N/A
  • MANH $266.94
  • Technical
  • Relative Strength Index (RSI)
  • XOMAP 47.85
  • MANH 32.17
  • Support Level
  • XOMAP $25.32
  • MANH $215.62
  • Resistance Level
  • XOMAP $25.90
  • MANH $245.00
  • Average True Range (ATR)
  • XOMAP 0.37
  • MANH 6.18
  • MACD
  • XOMAP -0.06
  • MANH -3.73
  • Stochastic Oscillator
  • XOMAP 21.50
  • MANH 8.51

About XOMAP XOMA Corporation 8.625% Series A Cumulative Perpetual Preferred Stock

XOMA Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceuticals or biotechnology companies. When XOMA acquires future economic rights, the seller receives non-dilutive, non-recourse funding that can use to advance their internal drug candidate(s) or for general corporate purposes.

Share on Social Networks: